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Abstract 
Background. We evaluated the implications of different approaches to characterize uncertainty of 
calibrated parameters of stochastic decision models (DMs) and quantified the value of such uncertainty in 
decision making. Methods. We used a microsimulation DM of colorectal cancer (CRC) screening to 
conduct a cost-effectiveness analysis (CEA) of a 10-year colonoscopy screening. We calibrated the natural 
history (NH) model of CRC to epidemiological data with different degrees of uncertainty and obtained the 
joint posterior distribution of the parameters using a Bayesian approach. We conducted a probabilistic 
sensitivity analysis (PSA) on all the model parameters with different characterizations of uncertainty of the 
calibrated parameters and estimated the value of uncertainty of the different characterizations with a value 
of information analysis. All analyses were conducted using high performance computing (HPC) resources 
running the Extreme-scale Model Exploration with Swift (EMEWS) framework. Results. The posterior 
distribution had high correlation among some parameters. The parameters of the Weibull hazard function 
for the age of onset of adenomas had the highest posterior correlation of -0.958. Considering full 
posterior distributions and the maximum-a-posteriori estimate of the calibrated parameters, there is little 
difference on the spread of the distribution of the CEA outcomes with a similar expected value of perfect 
information (EVPI) of $653 and $685, respectively, at a WTP of $66,000/QALY. Ignoring correlation on 
the posterior distribution of the calibrated parameters, produced the widest distribution of CEA outcomes 
and the highest EVPI of $809 at the same WTP. Conclusions. Different characterizations of uncertainty 
of calibrated parameters have implications on the expect value of reducing uncertainty on the CEA. 
Ignoring inherent correlation among calibrated parameters on a PSA overestimates the value of 
uncertainty.  
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BACKGROUND 
Decision models (DMs) are commonly used in cost-effectiveness analysis where uncertainty in 
the parameters is inherent (1). The impact of parameter uncertainty can be assessed with probabilistic 
sensitivity analysis (PSA) to characterize decision uncertainty (i.e., the probability of a strategy being 
cost-effective) and to quantify the value of potential future research by determining the potential 
consequences of a decision with value of information (VOI) analysis (2,3).  
The parameters of DMs can be split into two categories, those that are obtained from the 
literature or can be estimated from available data (i.e., external parameters), and those that need to be 
estimated through calibration (i.e., calibrated parameters). Uncertainty of external parameters is 
estimated either from individual-level or aggregated data that directly inform the parameters of interest. 
There are recommendations on the type of distributions that characterize their uncertainty based on the 
characteristics of the parameters or the statistical model used to estimate them (3). For example, a 
probability could be modeled with a beta distribution and a relative risk with a lognormal distribution 
(4). For calibrated parameters, no such data exist that can directly inform their uncertainty because a 
research study hasn’t been conducted or is unfeasible to conduct, or because the parameters reflect 
unobservable phenomena, as is often the case in natural history models of chronic diseases (5–8) or in 
infectious disease dynamic models (9). The choice of distribution for these parameters is often less 
clear. One option is to define uniform distributions with wide bounds or generate informed 
distributions based on moments of the calibrated parameters, such as the mean and standard error. 
However, the impact of these approaches to characterize uncertainty of calibrated parameters on 
decision uncertainty and VOI has not been studied. 
Model calibration is the process of estimating these parameters by matching model outputs to 
observed clinical or epidemiological data (known as calibration targets) (1,10–12). While there are 
several approaches for searching the parameter space in the calibration process, most approaches are 
insufficient when one wants to characterize the uncertainty in the calibrated model parameters because 
they do not provide interval estimates. For example, direct-search optimization algorithms like Newton-
Raphson, Nelder-Mead (13), simulated annealing or genetic algorithms (14) treat the calibration targets 
as if they were known with certainty, so are primarily useful when one wants to identify a single or a set 
of parameter sets that yield good fit to the targets (10).  
A sample of calibrated parameter sets that correctly characterizes the uncertainty of all of the 
calibration target data has to be obtained from their joint distribution conditional on the calibrated 
targets. To obtain this joint distribution of the calibrated parameters, the calibration could be seen as a 
statistical estimation problem under two different frameworks, through maximum likelihood (ML) or 
Bayesian methods. ML can fail in obtaining interval estimates for stochastic models and when the 
calibration problem is non-identifiable (12,15); thus, we will focus on a Bayesian approach.  
In a Bayesian-calibration framework, instead of obtaining a single best-fitting parameter or a set 
of good parameter sets, the solution is a joint (posterior) probability distribution (10,16,17) of calibrated 
parameters that adequately characterizes the uncertainty of all of the calibration targets (10,18–21) and 
prior information about the model parameters (22). A Bayesian approach is able to characterize 
uncertainty of calibrated parameters even in the presence of non-identifiability (12, 15,23). Despite their 
suitability to correctly characterize uncertainty of calibrated model parameters, Bayesian methods are 
computationally expensive because of the need to evaluate the model thousands and sometimes 
millions of times. The computational burden of Bayesian methods does not seem to be an impediment 
when calibrating deterministic DM (17,24) but they become more difficult to apply to stochastic DMs, 
such as microsimulation, discrete-event simulation and agent-based models, which has limited its use to 
a few of them (5).  
However, the increasing availability of high-performance computing (HPC) systems both in 
academic and commercial settings expands the use of such systems for model calibration and model 
exploration of stochastic DMs to a broader audience. The Extreme-scale Model Exploration with Swift 
(EMEWS) framework facilitates such large-scale model calibration and exploration on HPC resources 
(25). EMEWS (emews.org) offers the capability to run very large, highly concurrent ensembles of 
stochastic DMs of varying types while supporting a wide class of calibration algorithms, including those 
increasingly available to the community via Python and R libraries, on high-performance computing 
clusters. 
The purpose of our study is twofold. First, to use recently developed HPC capabilities to 
characterize uncertainty of calibrated parameters of a microsimulation model of the natural history 
(NH) of colorectal cancer (CRC). Second, to explore the impact of different approaches to 
characterizing the uncertainty of calibrated parameters on decision uncertainty and to quantify the value 
of eliminating parameter uncertainty using VOI analysis using a stochastic DM for the cost-
effectiveness of CRC screening strategies.  
METHODS 
We developed a microsimulation model of the NH of CRC and calibrated it using a Bayesian 
approach. Instead of using the posterior means to represent the best estimates of each calibrated 
parameter, we obtained the posterior distribution using a Bayesian approach that represents the joint 
uncertainty of all of the calibrated parameters that can then be used in a PSA. We then overlaid a simple 
CRC screening strategy onto the NH model and conducted a cost-effectiveness analysis (CEA) of the 
CRC screening strategy, including a PSA. We then evaluated the impact of different approaches to 
characterize uncertainty of calibrated parameters on the joint distribution of incremental costs and 
incremental effects of the screening strategy compared with no screening through a PSA while also 
accounting for the uncertainty of the external parameters (e.g., test characteristics, costs, etc.). We also 
quantified the value of eliminating all parameter uncertainty by calculating the expected value of perfect 
information (EVPI). 
Microsimulation model of the natural history of CRC 
We developed a state-transition microsimulation model of the NH of CRC implemented in R (26) 
based on a structure of a previously implemented deterministic model (12). The progression between 
health states follows a continuous-time age-dependent Markov process. There are two age-dependent 
transition intensities (i.e., transition rates), 𝜆"(𝑎) and 𝜇(𝑎), that govern the age of onset of adenomas 
and non-cancer-specific mortality, respectively. Following Wu et al. (27), we specify 𝜆"(𝑎) as a Weibull 
hazard with the following specification  𝜆"(𝑎) = 𝑙𝛾𝑎*+", 
where 𝑙 and 𝛾 are the scale and shape parameters of the Weibull hazard function, respectively. The 
model simulates two adenoma categories: small (adenoma smaller than 1 cm in size) and large 
(adenoma larger than or equal to 1 cm in size). All adenomas start small and can transition to the large 
size category at a constant annual rate 𝜆-. Large adenomas may become preclinical CRC at a constant 
annual rate 𝜆.. Both, small and large adenomas may progress to preclinical CRC, although most will not 
in an individual’s lifetime. Early preclinical cancers (preclinical stages I and II) progress to late stages 
(preclinical stages III and IV) at a constant annual rate 𝜆/ and could become symptomatic at a constant 
annual rate 𝜆0. Late preclinical cancer could become symptomatic at a constant annual rate 𝜆1. After 
clinical detection, the model simulates the survival time to death from early and late CRC using time-
homogeneous mortality rates, 𝜆2 and 𝜆3, respectively. In total, the model has nine health states: normal, 
small adenoma, large adenoma, preclinical early CRC, preclinical late CRC, clinical early CRC, clinical 
late CRC, CRC death and death from other causes. The state-transition diagram of the model is shown 
in Figure 1. 
 
Figure 1. State-transition diagram of the nine-state microsimulation model of the natural history of 
colorectal cancer. Individuals in all health states face an age-specific mortality of dying from other 
causes (state not shown). 
The continuous-time age-dependent Markov process of this NH model of CRC can be 
represented by an age-dependent 9 × 9 transition intensity matrix, 𝑄(𝑎). To translate 𝑄(𝑎) to discrete 
time, we compute the annual-cycle age-dependent transition probability matrix, 𝑃(𝑎, 𝑡), using the 
Kolmogorov differential equations (7,28,29) 𝑃(𝑎, 𝑡) = Exp9𝑡𝐺(𝑎);, 
where 𝑡 = 1 and Exp() is the matrix exponential. In discrete time, the microsimulation model of the 
NH of CRC allows transitions across multiple health states in a single year. That is, small and large 
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adenomas may progress to preclinical or clinical CRC and preclinical cancers may progress through 
early and late stages.  
We simulated a hypothetical cohort of 50-year-old women in the US over a lifetime. The cohort 
starts the simulation with a prevalence of adenoma of 𝑝>?@AB, from which a proportion, 𝑝CD>EE , 
correspond to small adenomas and prevalence of preclinical early and late CRC of 0.12% and 0.08%, 
respectively. The simulated cohort is at risk of non-CRC mortality from all health states. We obtained 
all-cause mortality, 𝜇(𝑎), from 2014 US life tables.(30) 
Calibration targets 
To calibrate the parameters of the microsimulation model of the NH of CRC, we conducted a 
confirmatory simulation by choosing a set of parameters based on plausible estimates from Wu et al. 
(27) and using the model to simulate four different age-specific targets, including adenoma prevalence, 
proportion of small adenomas and CRC incidence for early and late stages, which resemble commonly 
used calibration targets for this type of model (5, 24,31,32). To simulate the calibration targets, we ran 
the microsimulation model 100 times to get a stable estimate of the standard errors (SEs) using the 
fixed values in Table 1. We then aggregated the results across all 100 outputs to compute their mean 
and SE. Different calibration targets could have different level of uncertainty given the amount of data 
to compute their summary measures. Accordingly, we simulated different types of targets based on 
cohorts of different sizes to account for different variations in the amount of data on different 
calibration targets. Adenoma-related targets were based on a cohort of 500 individuals and cancer 
incidence targets were based on a cohort of 100,000 individuals. 
Symbol Description Value Source Prior Distribution Calibrated 
Initial state of 50-year-old cohort 
Proportions 𝑝>?@AB Prevalence of adenoma at age 50 0.25 (33) Beta(3, 8) Yes 𝑝CD>EE Proportion adenomas that are small at age 50 0.71 (27) Beta(6, 3) Yes 
- Prevalence of preclinical early CRC at age 50 0.12  Fixed 
No 
- Prevalence of preclinical late 
CRC at age 50 
0.08  Fixed No 
Disease dynamics 
Transition rates (annual) 𝑙 Scale parameter of Weibull hazard 2.86e-06 (27) Log-normal(m=-11.97, s=0.59) Yes 𝛾 Shape parameter of Weibull hazard 2.78 (27) Log-normal(m=1.04, s=0.18) Yes 𝜆- Small adenoma to large adenoma 0.0346 (27) Log-normal(m=-3.45, s=0.59) Yes 
𝜆. Large adenoma to preclinical early CRC 0.0215 (27) Log-normal(m=-3.91, s=0.35) Yes 𝜆/ Preclinical early CRC to preclinical late CRC 0.3697 (27) Log-normal(m=-1.15, s=0.23) Yes 𝜆0 Preclinical early CRC to clinical late CRC 0.2382 (27) Log-normal(m=-1.41, s=0.10) Yes 𝜆1 Preclinical late CRC to clinical late CRC 0.4582 (27) Log-normal(m=-0.78, s=0.22) Yes 𝜆2 CRC mortality in early stage 0.0302 (27) Fixed No 𝜆3 CRC mortality in late stage 0.2099 (27) Fixed No 𝜇(𝑎) Age-specific mortality Age-specific (34) Fixed No 
Table 1. Description of parameters of the microsimulation model of the natural history of colorectal 
cancer. 
Calibration of the microsimulation model of the NH of CRC 
To state the calibration of the microsimulation model as an estimation problem (12), we define 𝑀 as 
the microsimulation model of the NH of CRC that has 11 input parameters 𝜃 ∈ ℝ"". Mortality rates 
from early and late stages of CRC could be obtained from cancer population registries (e.g., SEER in 
the U.S.), so there is no need to calibrate these. That is, 𝜃J = [𝜆2, 𝜆3] is a set of 2 parameters that are 
known or could be obtained from external data (i.e., are external parameters). The model has a set of 9 
parameters 𝜃M = [𝑝>?@AB, 𝑝CD>EE, 𝑙, 𝛾, 𝜆-, 𝜆., 𝜆/, 𝜆0, 𝜆1] that cannot be directly estimated from sample 
data and need to be calibrated. The total number of parameters of 𝑀 is 𝜃 = [𝜃M, 𝜃J]. 
To calibrate	𝑀, we adopted a Bayesian approach that allowed us to obtain a joint posterior 
distribution that characterizes the uncertainty of both the calibration targets and previous knowledge of 
the parameters of interest in the form of prior distributions. Prior distributions can reflect expert 
opinion or when little knowledge is available, these could be specified as uniform distributions. 
Following previous specifications, we constructed the likelihood function by assuming that the targets, 𝑦PQ , are normally distributed with mean 𝜙PQ and standard deviation 𝜎PQ (12). That is,   𝑦PQ ∼ Normal9𝜙PQ, 𝜎PQ;, 
where 𝜙PQ = 𝐄[𝑀(𝜃)] is the expected value of the model-predicted output for each type of target 𝑡 and 
age group 𝑖 at parameter set 𝜃. To compute an aggregated likelihood measure, we added the log-
likelihoods across all targets. We defined prior distributions for all 𝜃M based on previous knowledge or 
nature of the parameters. For the prevalence of adenomas and proportion of small adenomas at age 50, 
we defined beta distributions, so they are bounded between 0 and 1. For the annual transition rates, 
which are defined over positive numbers, we assumed that their prior distributions follow a log-normal 
distribution. The prior distributions for these parameters are shown in Table 1. The ranges given in 
Table 1 are assumed to represent the 95% equal-tailed interval for the beta and log-normal 
distributions. 
To conduct the Bayesian calibration, we used the incremental mixture importance sampling 
(IMIS) algorithm (35), which has been previously used to calibrate deterministic health policy models 
(17). An advantage of IMIS over other Monte Carlo methods, such as Markov chain Monte Carlo, is 
that with IMIS the evaluation of the likelihood for different sampled parameter sets could be 
parallelized, which makes its implementation perfectly suitable for an HPC environment using 
EMEWS. 
Propagation of uncertainty  
To characterize the joint uncertainty of the seven calibrated model parameters, we sampled 
5,000 parameter sets from their joint posterior distribution using the IMIS algorithm. To compare the 
outputs of the calibrated model against the calibration targets, we propagated the uncertainty of the 
calibrated parameters through the microsimulation model of the NH of CRC by simulating a cohort of 
100,000 individuals and computing the model-predicted adenoma and cancer outcomes for each of the 
5,000 calibrated parameter sets drawn from their joint posterior distribution. To estimate the 
uncertainty limit model outputs, we computed the 95% posterior predicted interval (PI) defined as the 
estimated range between the 2.5th and 97.5th percentiles of the model-predicted posterior outputs. 
Cost-effectiveness analysis of screening for CRC 
With the calibrated microsimulation model of the NH of CRC, we assessed the cost-effectiveness of 
10-yearly colonoscopy screening starting at age 50 years compared to no screening using a stochastic 
DM. For adenomas detected with colonoscopy, a polypectomy was performed during the procedure. 
Individuals diagnosed with a low- or high-risk polyp (i.e., small or large adenoma, respectively) 
underwent surveillance with colonoscopy every 5 or 3 years, respectively. We assumed screening or 
surveillance continued until 85 years of age. Recurrence rates after polypectomy were higher for 
individuals with a history of a polyp diagnosis. Only the transition rate from normal to small adenoma 
(i.e., 𝜆"(𝑎)) was increased among those with a history of polyp. We assumed a hazard ratio (HR) of 2 
for low-risk polyp and a HR of 3 for high-risk polyp. The costs of CRC treatment and utilities for CRC 
varied by stage. Patients without clinical CRC had a utility of 1. Table 2 shows the parameters used in 
the CEA with their corresponding distributions. 
Parameter Value (Range) Distribution  Source 
Screening test characteristics (location-specific) 
Small adenomas 
Sensitivity 0.773 (0.734-0.808) Beta  (35) 
Specificity 0.868 (0.855-0.880) Beta (36) 
Large adenomas and CRC 
Sensitivity 0.950 (0.920-0.990) Beta (35) 
Specificity 0.868 (0.855-0.880) Beta (36) 
Increased rates after polypectomy (hazard ratio) 
Low risk 2 (1-3) Log-normal Assumed 
High risk 3 (2-4) Log-normal Assumed 
Costs ($) 
Colonoscopy 10,000 (9,000-11,000) Log-normal Assumed 
Early clinical CRC, annual costs 21,524 (20,000-23,000) Log-normal Assumed 
Late clinical CRC, annual costs 37,000 (35,000-39,000) Log-normal Assumed 
Utilities 
Preclinical CRC 1.000 (0.980-1.000) Log-normal Assumed 
Early clinical CRC 0.855 (0.700-0.900) Log-normal (37) 
Late clinical CRC 0.300 (0.200-0.400) Log-normal (37) 
Table 2. Description of cost-effectiveness analysis parameters 
We conducted different PSA of the 10-year colonoscopy screening strategy for different 
approaches to characterize uncertainty of the two types of parameters, the calibrated and external (i.e., 
CEA parameters) using EMEWS to distribute the samples of each PSA across HPC resources. The first 
approach considers uncertainty in both types of parameters. The uncertainty of the calibrated 
parameters was characterized by their joint posterior distribution obtained from the IMIS algorithm. 
The second approach only considers uncertainty in the external parameters while fixing the calibrated 
parameters the maximum-a-posteriori (MAP) estimate (i.e., the parameter with the highest posterior 
density). The third approach considers uncertainty only in the calibrated parameters characterized by 
their joint posterior distribution and no uncertainty in the external parameters, which are fixed at their 
mean values. The fourth approach considers uncertainty in both types of parameters but compared to 
the first approach, the uncertainty of the calibrated parameters is characterized by constructing 
distributions based solely on posterior moments (i.e., means and standard deviations) and type of 
calibrated parameters ignoring correlations. We then estimated the EVPI of the 10-year colonoscopy 
screening strategy for the different approaches to characterize uncertainty of the calibrated and external 
parameters. 
RESULTS 
The IMIS algorithm was run on the Midway2 cluster at the University of Chicago Research Computing 
Center. Midway2 is a hybrid cluster, including both CPU and GPU resources. For this work, the CPU 
resources were used. Midway2 consists of 370 nodes of Intel E5-2680v4 processors, each with 28 cores 
and 64 GB of RAM. Using EMEWS we developed a workflow that parallelized the likelihood 
evaluations over 1008 processes using 36 compute nodes in total. We based the estimation of the 
calibrated parameters on 5,000 parameter sets sampled from the posterior distribution, including 3,241 
unique parameter sets with an expected sample size (ESS) of 2,098.  
Figure 2 shows the marginal prior and posterior distributions of the calibrated parameters. Table 3 
gives estimated posterior means and standard deviations, MAP estimates and 95% credible intervals 
(CrI) for all calibrated parameters. From Table 3 and Figure 2, the prior and posterior means of the 
calibrate parameter do not seem that different but the major contrast is that the width of the posterior 
distributions shrunk, meaning that the calibration targets informed the calibrated parameters through a 
Bayesian updating.  
Parameter Mean SD MAP 
95% CrI 
LB UB 𝑝>?@AB 0.264 0.008 0.264 0.248 0.281 𝑝CD>EE 0.706 0.019 0.711 0.667 0.741 𝑙 6.24E-06 3.16E-06 4.52E-06 1.92E-06 1.41E-05 𝛾 2.639 0.112 2.635 2.432 2.877 𝜆- 0.035 0.002 0.035 0.031 0.039 𝜆. 0.021 0.001 0.021 0.020 0.023 𝜆/ 0.374 0.036 0.368 0.310 0.448 𝜆0 0.247 0.021 0.251 0.209 0.288 𝜆1 0.457 0.076 0.435 0.345 0.664 
Table 3. Posterior means, standard deviations, maximum-a-posteriori (MAP) estimate and 95% credible 
interval (CrI) of calibrated parameters of the microsimulation model of the natural history of colorectal 
cancer. 
 
Figure 2. Prior and posterior marginal distributions of calibrated parameters of the microsimulation 
model of the natural history of colorectal cancer. 
The Bayesian calibration also correlated the parameters showing the dependency among some of 
them, which can be seen on Figure 3 that shows the marginal and pair-correlations of the posterior 
distributions of the calibrated parameters. There are pairs of parameters with high correlation. The scale 
and shape parameters of the Weibull hazard function for the age of onset of adenomas, 𝑙 and 𝛾, 
respectively, have the highest negative correlation of -0.958. The high correlation is the result from the 
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calibration of the microsimulation model of the NH of CRC being non-identifiable when calibrating all 
9 parameters to all the targets (see Alarid-Escudero et al. (12) for a detailed description of this analysis). 
The transition rates from preclinical early CRC to preclinical late and clinical early have a correlation of 
0.784. The prevalence of adenomas and the proportion of small adenomas at age 50, which inform the 
initial distribution of the cohort across the adenoma health states, also have a high correlation of 0.482.  
 
Figure 3. Scatter plot of pairs of calibrated parameters with correlation coefficient and posterior 
marginal distributions. 
Figure 4 shows the internal validation of the calibrated model by comparing calibration targets with 
their 95% confidence interval (CI) and the model-predicted posterior means together with their 95% 
posterior PI. The calibrated model accurately predicted the calibration targets for both the means and 
the uncertainty intervals.  
 
Figure 4. Comparison between posterior model-predicted outputs and calibration targets. Calibration 
targets with their 95% CI are shown in black. The shaded area shows the 95% posterior model-
predictive interval of the outcomes and colored lines shows the posterior model-predicted mean based 
on 5,000 simulations using samples from posterior distribution. Upper panel refers to adenoma-related 
targets and lower panel refers to CRC incidence targets by stage. 
The joint distribution of the incremental QALYs and incremental costs of the 10-year colonoscopy 
screening strategy resulting from the PSA for the different approaches to characterize uncertainty of the 
calibrated parameters are shown in Figure 5Figure 5 When accounting for uncertainty on the external 
parameters, there is little difference on the spread of the CEA outcomes between considering the joint 
distribution of the calibrated parameters and using only the MAP estimates (approaches 1 and 2 on the 
top row of Figure 5, respectively). The joint distribution of the outcomes is slightly wider when 
considering uncertainty on all parameters compared to when fixing the calibrated parameters at their 
MAP estimate. The third approach reflects the impact of only varying the calibrated parameters on the 
joint distribution of incremental QALYS and incremental costs, which is much more narrow compared 
to approaches 1 and 2. The fourth approach, which characterizes uncertainty of the calibrated 
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parameters using method of moments without accounting for correlation, has the widest spread on the 
distribution of the outcomes.  
 
Figure 5. Incremental costs and incremental QALYs of 10-year colonoscopy screening vs no screening 
under different assumptions of characterization of uncertainty of both calibrated and external 
parameters. Red star corresponds to the incremental costs and incremental QALYs evaluated at the 
maximum-a-posteriori estimate of the calibrated parameters and the mean values of the external 
parameters. 
Figure 6 shows the per-person EVPI of the 10-year colonoscopy screening strategy as a function of 
the willingness-to-pay (WTP) threshold for the four different approaches to characterize uncertainty of 
the calibrated and the external parameters. The first and second approach had similar EVPI up to 
reaching their maximum of $653 and $685, respectively, at a WTP threshold of $66,000/QALY. For 
WTP thresholds greater than $66,000/QALY, the first approach had higher EVPI than the second 
approach. When only uncertainty is considered for the calibrated parameters (approach 3), the EVPI is 
the lowest across all WTP thresholds with an EVPI of $0.1 at a WTP threshold of $66,000/QALY and 
reaching its highest of $212 at a WTP threshold of $71,000/QALY. The fourth approach reaches a 
maximum of $809 at a WTP threshold of $66,000/QALY and is the highest compared to the other 
approaches up to a WTP threshold of $81,000/QALY at which the first approach has the highest 
EVPI. 
 
Figure 6. Per-patient EVPI of 10-year colonoscopy screening vs. no screening under different 
approaches to characterize uncertainty of both the calibrated and external parameters.  
DISCUSSION 
In this study, we characterized the uncertainty of a relatively simple but realistic 
microsimulation model of the NH of CRC by calibrating its parameters to different targets with varying 
degrees of uncertainty using a Bayesian approach on an HPC environment using EMEWS and 
quantified the value of the uncertainty of the calibrated parameters on the cost-effectiveness of a 10-
year colonoscopy screening strategy. Although Bayesian calibration is a computationally intensive task, 
we took advantage of the parallelizability of the IMIS algorithm to efficiently conduct this task by 
evaluating the likelihood of different parameter sets in multiple cores simultaneously on an HPC setup. 
EMEWS has been previously used to calibrate other stochastic DMs (39,40) but has not been 
previously used to conduct PSA and calculate the VOI of calibrated parameters. 
We found that different characterizations of uncertainty of calibrated parameters have implications 
on the expect value of reducing uncertainty on the CEA. Ignoring inherent correlation among 
calibrated parameters on a PSA overestimates the value of uncertainty. When full posterior 
distributions of the calibrated parameters are not readily available, the MAP could be considered as a 
best parameter set. In our example, not considering uncertainty of calibrated parameters on the PSA 
did not seem to have a meaningful impact on the uncertainty of the CEA outcomes and the EVPI of 
the screening strategy. That is, the uncertainty associated with the NH was less valuable than the 
uncertainty of the external parameters. However, these results should be taken with caution because 
this analysis is conducted on a fictitious model with simulated calibrated targets. The impact of a well 
conducted characterization of the uncertainty of calibrated parameters on CEA outcomes and VOI 
measures should be analyzed on a case-by-case basis. 
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There are examples of calibrated parameters being included in a PSA. For example, by taking a 
certain number of good-fitting parameter sets (41,42), bootstrapping with equal probability good-fitting 
parameter sets obtained through directed search algorithms (e.g., Nelder-Mead) (43), or conducting a 
Bayesian calibration, which produces the joint posterior distribution of the calibrated parameters 
(17).However, this is the first manuscript to conduct a PSA and VOI analysis using distributions of 
calibrated parameters of a stochastic DM that accurately characterize their uncertainty. 
Currently, Bayesian calibration of stochastic DMs might not be feasible on regular desktop or 
laptop computers. To circumvent current computational limitations from using Bayesian methods in 
calibrating stochastic DM, the use of surrogate models -often called metamodels or emulators- has been 
proposed (44,45). Surrogate models are statistical models like Gaussian processes (46) or neural 
networks (47) that aim to replace the relation between inputs and outputs of the original stochastic DM 
(48,49), which once fitted they are computationally more efficient to run than the stochastic DM. 
Constructing an emulator might not be a straightforward task because the stochastic DM still needs to 
be evaluated at different parameter sets which could also be computationally expensive. Furthermore, 
the statistical routines to build the emulator may not be readily available in the programming language 
in which the stochastic DM is coded. These are the type of situation where EMEWS can be used to 
efficiently construct metamodels. This, however, is a topic for further research 
In this article, we showed that EMEWS can facilitate the use of HPC to implement computationally 
demanding Bayesian calibration routines to correctly characterize the uncertainty of the calibrated 
parameters of stochastic DMs and propagate it in the evaluation of CEA of screening strategies and 
quantify their value of information. The methodology and results of this study could be used to guide a 
similar VOI analysis on a more realistic, hence more complicated, stochastic DM of CRC screening to 
determine where more research is needed and guide research prioritization.  
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